August 25, 2022

Announcing The ONO Pharma Prospect Trial for PCNSL

Current treatment options for primary CNS lymphoma (PCNSL) are limited, and there are no medications approved specifically for the treatment of PCNSL in the United States. New treatment options are needed to improve the prognosis for those with PCNSL.

The PROSPECT study is a clinical trial to evaluate an investigational oral medicine called tirabrutinib in patients with PCNSL. About 112 participants will be enrolled in the Phase II (PROSPECT) study in the United States.

End Brain Cancer Mobile App is Here

Stay informed and engaged with EBCI, download our new mobile app.

Download the app

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614

DONATE

Our Case For Change

EBCI In The News

Patient Support Services

Patient Resource Center

VOLUNTEER WITH EBCI

GET IN TOUCH

corporate partners

upcoming events

resources

About us